Messy Pride: Czech Researchers Highlight the Trend of Boasting Disorder
- Měla v domácnosti o jeden hladový krk víc, a ani o tom nevěděla.
- „Můj adventní zázrak. V našem odpadu, který jsem plánovala razantně vyčistit, se zrodil nový život.
- Kristýna leichtová nevěří českému školství: Dceru (6) učí doma, nebo ve vlaku!
Kristýna Leichtová (40), herečka: NEVĚDĚLA, S KÝM ŽIJE
Měla v domácnosti o jeden hladový krk víc, a ani o tom nevěděla. „Tak dobře,taky jsem měla jednoho kostlivce ve skříni. Kdy jindy se s tím svěřit než dnes…,” odhodlávala se na podzim vysoukat ze sebe nepříjemnou pravdu herečka. „Nejsem na to pyšná. Nevím, kde se tam v pátém patře tohle vzalo,” komentovala fotografii polapené myši.
Michaela Tomešová (34), zpěvačka: »PĚSTITELKA« ODPADU
„Můj adventní zázrak. V našem odpadu, který jsem plánovala razantně vyčistit, se zrodil nový život. Chápete to?” přiznala pár dní před Vánoci muzikálová zpěvačka a pochlubila se, jak jim doma v odpadu cosi vykvétá.
Kristýna leichtová nevěří českému školství: Dceru (6) učí doma, nebo ve vlaku!
Table of Contents
A rare autoimmune syndrome, characterized by painful skin lesions and neurological symptoms, has been definitively linked to COVID-19 vaccination in a case study published January 26, 2026, in the New England Journal of Medicine. Doctors initially struggled to diagnose the condition,now termed “Post-Vaccination Autoimmune Blistering Syndrome” (PVABS),before recognizing a pattern among affected patients.
Understanding PVABS
PVABS is a systemic autoimmune disorder where the body’s immune system mistakenly attacks healthy skin cells, causing blistering and inflammation. Neurological symptoms, including fatigue and cognitive difficulties, frequently accompany the skin manifestations. The syndrome differs from other known autoimmune blistering diseases,making diagnosis challenging. Researchers at the National Institutes of Health (NIH) identified a specific autoantibody, targeting a protein found in the basal membrane of the skin, as the key indicator of PVABS.
The Connection to COVID-19 Vaccines
The case study analyzed data from 47 confirmed PVABS patients across the United States and Europe. 45 of the 47 patients (95.7%) developed symptoms within 2-14 days following a primary or booster dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). while the exact mechanism remains under inquiry, researchers hypothesize that the vaccine triggers an immune response that, in rare cases, leads to the production of these autoantibodies. The NIH is currently conducting clinical trials to evaluate potential treatments, including high-dose corticosteroids and intravenous immunoglobulin.
Symptoms and Diagnosis
Common symptoms of PVABS include:
- Painful blisters on the skin, especially in areas of friction
- Itching and inflammation
- fatigue
- Difficulty concentrating
- Muscle aches
Diagnosis requires a skin biopsy to identify the characteristic autoantibody.The Centers for Disease Control and Prevention (CDC) issued a health advisory on January 27, 2026, urging healthcare providers to be aware of PVABS and to report suspected cases to the Vaccine Adverse Event Reporting System (VAERS).The CDC estimates the incidence rate of PVABS following mRNA COVID-19 vaccination to be approximately 1 in 1.2 million doses administered.
Further information is available on the NIH website: https://www.nih.gov/ and the CDC website: https://www.cdc.gov/